Form 4: Co-Diagnostics Director Richard Serbin Increases Common Stock Holdings Through RSU Vesting

Co-Diagnostics, Inc. Director Richard S. Serbin reported the acquisition of 48,334 shares of common stock on May 23, 2025, resulting from the vesting of previously awarded Restricted Stock Units (RSUs), increasing his direct beneficial ownership to 214,167 shares.

Summary

• Richard S. Serbin, a Director of Co-Diagnostics, Inc. (CODX), acquired 48,334 shares of common stock on May 23, 2025.
• The acquisition was a result of the vesting of Restricted Stock Units (RSUs) at a price of $0.00 per share, indicating equity compensation.
• Following this transaction, Mr. Serbin directly beneficially owns 214,167 shares of Co-Diagnostics common stock.
• He also holds 103,333 unvested Restricted Stock Units.
• The vested shares are part of RSU awards granted on July 7, 2022 (70,000 units), January 17, 2023 (40,000 units), June 12, 2023 (70,000 units), and April 26, 2024 (110,000 units), which vest in six equal installments every six months.
• The vesting on May 23, 2025, aligns with the vesting schedule for the January 17, 2023 RSU award, which commenced vesting on May 23, 2023.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as it reflects a routine vesting of equity compensation, increasing insider ownership and aligning management interests with shareholders, without indicating any unexpected negative events.

Positives

• The transaction represents an increase in direct beneficial ownership of Co-Diagnostics common stock by a director, aligning management's interests with shareholders.
• The vesting of Restricted Stock Units is a routine part of executive compensation, indicating the fulfillment of long-term incentive plans.

Future Outlook

The document does not provide forward-looking statements or guidance beyond the scheduled vesting of existing RSU awards.

Industry Context

This Form 4 filing is a routine disclosure of insider stock ownership changes and does not provide information on broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders: Increased direct ownership by a director may be viewed positively as it aligns management's incentives with shareholder value creation.

Next Steps

• Future vesting events for the remaining 103,333 Restricted Stock Units held by Richard Serbin, according to their respective six-month installment schedules.

Key Dates

Keywords

Co-Diagnostics, CODX, Richard Serbin, Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, Beneficial Ownership, Director Stock Holdings, Equity Compensation